Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
What to Expect From Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.
Get Ready To Be Surprised This Earnings Season
by Kevin Matras
Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include EXAS, MOD, B, OC and HIIQ.
Zacks.com featured highlights include Nintendo Co., Exact Sciences, Tabula Rasa Healthcare, Facebook and Nova Measuring Instruments
by Zacks Equity Research
Zacks.com featured highlights include Nintendo Co., Exact Sciences, Tabula Rasa Healthcare, Facebook and Nova Measuring Instruments
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
5 Top-Ranked Profitable Stocks to Boost Your Portfolio
by Zacks Equity Research
Profitability analysis is used to measure the company's ability to manage its revenues effectively and provide stunning returns to its investors.
Shire's New Formulation of Oncaspar Gets CHMP Recommendation
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
MiMedx Group (MDXG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
MiMedx Group (MDXG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Pluristem Therapeutics Inc. (PSTI) saw its shares rise over 5% on the day.
Can Exact Sciences (EXAS) Keep the Earnings Streak Alive This Quarter?
by Zacks Equity Research
Exact Sciences (EXAS) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)
by Zacks Equity Research
Exact Sciences Corporation (EXAS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?
by Zacks Equity Research
ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.
Why Exact Sciences (EXAS) Might Surprise This Earnings Season
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
New Strong Buy Stocks for July 19th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Exact Sciences (EXAS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
Exact Sciences (EXAS) Shows Strength: Stock Gains 11.7%
by Zacks Equity Research
Exact Sciences Corp. (EXAS) shares jumped almost 12% in the last trading session.
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
by Zacks Equity Research
Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.
Geron (GERN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.
Can Fitbit (FIT) Stock Surprise Investors Post Q4 Earnings?
by Zacks Equity Research
Fitbit Inc. (FIT) is set to report fourth-quarter 2016 results on Feb 22. Last quarter, the company posted a positive earnings surprise of 18.18%.
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23